Key facts
- Deep Track Capital, LP filed SCHEDULE 13G/A for Nektar Therapeutics Common Stock, par value $0.0001 (NKTR).
- Disclosed ownership: 1.1%.
- Date of event: 31 Dec 2024.
Deep Track Capital, LP - 31 Dec 2024 SCHEDULE 13G/A Report for Nektar Therapeutics Common Stock, par value $0.0001 (NKTR)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- NKTR
- Shares outstanding
- 184,672,710 shares
- Disclosed Ownership
- 1,975,998 shares
- Ownership
- 1.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 08:43:38 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Key filing fact
Deep Track Capital, LP disclosed 1.1% ownership in Nektar Therapeutics Common Stock, par value $0.0001 (NKTR) on 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 08:43.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 1.1% | 1,975,998 | 0 | 1,975,998 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 1.1% | 1,975,998 | 0 | 1,975,998 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 1.1% | 1,975,998 | 0 | 1,975,998 | /s/ David Kroin | David Kroin |
CIK / CUSIP context first